These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 16401151)

  • 1. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
    Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
    J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
    Pallanti S; Quercioli L; Koran LM
    J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
    Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
    J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.
    Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J
    J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder.
    Reddy YC; Alur AM; Manjunath S; Kandavel T; Math SB
    J Clin Psychopharmacol; 2010 Jun; 30(3):267-72. PubMed ID: 20473061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
    Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
    Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
    BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological management of obsessive-compulsive disorder: a review for clinicians.
    McDonough M; Kennedy N
    Harv Rev Psychiatry; 2002; 10(3):127-37. PubMed ID: 12023928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study.
    Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M
    J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of SLC1A1 gene polymorphism with obsessive compulsive disorder in a sample from southern India.
    Shukla T; Nadella RK; Taj M J RJ; Ganesh S; Nestadt G; Purushottam M; Jain S; Reddy YCJ; Viswanath B
    Exp Clin Psychopharmacol; 2020 Dec; 28(6):617-621. PubMed ID: 31985241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors of long-term outcome in obsessive-compulsive disorder.
    Jakubovski E; Diniz JB; Valerio C; Fossaluza V; Belotto-Silva C; Gorenstein C; Miguel E; Shavitt RG
    Depress Anxiety; 2013 Aug; 30(8):763-72. PubMed ID: 23109056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight and resistance in patients with obsessive-compulsive disorder.
    Catapano F; Sperandeo R; Perris F; Lanzaro M; Maj M
    Psychopathology; 2001; 34(2):62-8. PubMed ID: 11244376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.
    Masi G; Millepiedi S; Perugi G; Pfanner C; Berloffa S; Pari C; Mucci M
    CNS Drugs; 2009; 23(3):241-52. PubMed ID: 19320532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
    Hoehn-Saric R; Ninan P; Black DW; Stahl S; Greist JH; Lydiard B; McElroy S; Zajecka J; Chapman D; Clary C; Harrison W
    Arch Gen Psychiatry; 2000 Jan; 57(1):76-82. PubMed ID: 10632236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Aboujaoude E; Barry JJ; Gamel N
    J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.